Literature DB >> 2542198

Neurovisual outcome following proton radiation therapy.

I L Habrand1, M Austin-Seymour, S Birnbaum, S Wray, R Carroll, J Munzenrider, L Verhey, M Urie, M Goitein.   

Abstract

From February 1981 to January 1984, 20 patients with a tumor of the upper clivus received proton irradiation at the Harvard Cyclotron Laboratory. For 15 patients with known neurovisual status (including visual acuity, color vision, visual field, and fundus examinations) we obtained a cumulative dose-volume histogram (DVH) of the optic nerves (ON) and the optic chiasm. The prescribed tumor doses ranged from 66.6 to 74.4 Cobalt Gray Equivalent (CGE) with a daily fraction size of 1.8 to 2.1 CGE. CGE is used because modulated protons have an RBE of 1.1 compared to 60Co. The follow-up ranged from 30 to 68 months (median 52). Two patients developed, 10 and 36 months post irradiation, a progressive visual deterioration affecting both eyes. This was attributed to an ON and a chiasm injury in one patient and to bilateral ON injury in the other patient. In the first patient, the dose-volume analysis indicated that approximately half of the ON and of the chiasm had received 65 CGE and 55 CGE, respectively. In the second patient, it indicated that a quarter of the left ON (LON) had received 55 CGE whereas the dose to the right ON (RON) was significantly less. This patient had diabetes mellitus which may be a predisposing factor. From this study, a complication rate of 20% (1/5) is observed when a substantial portion of the ON is taken to 65 CGE, while it doesn't exceed 12.5% (2/16) and 7.5% (1/13) at 55 CGE for the ON and for the chiasm, respectively. This suggests a tolerance dose implying a 10% rate of major complications close to 55 CGE. When a tumor requires a high radiation-dose, the exclusion of these structures at 55 to 60 Gy is recommended.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2542198     DOI: 10.1016/0360-3016(89)90969-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

Review 1.  Uses of 3D planning in addition to creating a good treatment: ongoing studies at MGH/HCL.

Authors:  M M Urie
Journal:  Radiat Environ Biophys       Date:  1992       Impact factor: 1.925

2.  Risk factors for radiation-induced optic neuropathy: a case-control study.

Authors:  Ian Ferguson; Julie Huecker; Jiayi Huang; Collin McClelland; Gregory Van Stavern
Journal:  Clin Exp Ophthalmol       Date:  2017-03-09       Impact factor: 4.207

Review 3.  Proton therapy for tumors of the skull base.

Authors:  J E Munzenrider; N J Liebsch
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 3.621

4.  Feasibility of proton beam therapy for chordoma and chondrosarcoma of the skull base.

Authors:  Hiroshi Fuji; Yoko Nakasu; Yuji Ishida; Satoshi Horiguchi; Koichi Mitsuya; Hiroya Kashiwagi; Shigeyuki Murayama
Journal:  Skull Base       Date:  2011-05

5.  Radiation-induced bilateral optic neuropathy in cancer of the nasopharynx. Case failure analysis and a review of the literature.

Authors:  O B Wijers; P C Levendag; G P Luyten; B A Bakker; N J Freling; J Klesman-Bradley; E Woudstra
Journal:  Strahlenther Onkol       Date:  1999-01       Impact factor: 3.621

6.  Radiation-induced optic neuropathy after pencil beam scanning proton therapy for skull-base and head and neck tumours.

Authors:  Melpomeni Kountouri; Alessia Pica; Marc Walser; Francesca Albertini; Alessandra Bolsi; Ulrike Kliebsch; Barbara Bachtiary; Christophe Combescure; Antony J Lomax; Ralf Schneider; Damien Charles Weber
Journal:  Br J Radiol       Date:  2019-08-01       Impact factor: 3.039

7.  Sinonasal malignancies and charged particle radiation treatment: a systematic literature review.

Authors:  Marco Cianchetti; Maurizio Amichetti
Journal:  Int J Otolaryngol       Date:  2012-05-27

8.  Treatment outcomes of proton or carbon ion therapy for skull base chordoma: a retrospective study.

Authors:  Masaru Takagi; Yusuke Demizu; Fumiko Nagano; Kazuki Terashima; Osamu Fujii; Dongcun Jin; Masayuki Mima; Yasue Niwa; Kuniaki Katsui; Masaki Suga; Tomohiro Yamashita; Takashi Akagi; Koh-Ichi Sakata; Nobukazu Fuwa; Tomoaki Okimoto
Journal:  Radiat Oncol       Date:  2018-11-26       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.